The key reasons clinical trials fail are the inability to demonstrate efficacy and unexpected safety liabilities¹.
Our clinical biomarker panels offer a solution to overcome the obstacles of drug development and reliably monitor biomarkers.
The panels are flexible in size and can be multiplexed, enabling the simultaneous absolute quantification of up to 100 proteins. The panels can be customized across species and disease indications to best suit your research goals. The clinical biomarkers panels belong to the TrueSignature™ platform powered by Parallel Reaction Monitoring mass-spectrometry. The platform allows complete customization down to amino acid resolution (i.e., mutations, truncations, isoforms) and independence from affinity-based approach and reagent availability. You select the proteins, and we analyze them for you.
TrueSignature™ panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery™ studies guide the choice of proteins in the custom panel.
Resources
Deliverables
The results are presented and discussed with you in a dedicated conference call and delivered electronically in PDF and Excel format.
Executive Summary
Materials and Methods
(suitable for publication)Complete Data Matrix
a) Peptide and protein relative intensities for all study samples
b) Peptide and protein absolute quantities based on stable isotope standards (if applicable)
Data Interpretation
a) Differentially regulated proteins with regulation factor and p-value
b) Coefficient of variation analysis
c) Multivariate analysis (e.g., PCA)
d) Hierarchical clustering analysis
e) Custom analysis upon request
Sample types and depths
Clinical Biomarker Panel can be applied to virtually any kind of sample type and species with a minimum input of sample required.
Project management
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.
